The Ministry of Health has officially sent a request to the American company Tivic Health Systems about the drug Entolimod. It is being considered for inclusion in the strategic reserve as a treatment for acute radiation sickness. We tell you how this drug differs from its analogues and what we know about the developer.
The Ministry of Health initiates negotiations with Tivic Health
The Ministry of Health has sent Tivic Health Systems a formal request for detailed information about Entolimod. The Ukrainian agency also offered to hold a preliminary meeting on the potential supply of the drug. This demonstrates Ukraine's serious intentions to update its strategic stockpile of radiation protection products.
Why Entolimod is special
Entolimod is a Toll-like receptor 5 agonist that can protect not only the bone marrow but also the gastrointestinal tract, which is critical for survival in high radiation exposure. Unlike traditional drugs (Neupogen, Neulasta, Leukine), Entolimod can reduce gastrointestinal damage, making it a unique candidate for the strategic reserve. The drug has already received Fast Track and Orphan Drug designation from the FDA.
What you need to know about Tivic Health
Tivic Health Systems Inc. specialises in immunotherapeutic solutions and is currently conducting preclinical studies of Entolimod in collaboration with NIAID and the US Army Radiobiology Research Institute. Tivic Health has recently focused on biopharmaceuticals, moving away from consumer medical devices. In addition to radiation protection, Entolimod is planned to be used to support cancer patients during chemotherapy and radiotherapy.
Ukrainian
English